Stringers
Mobile App · iOS · written 11-15
Kurso: Antidepressant Tracker · Andrii Hermanov

Listed for 7 days with 1 ratings, reached #36 on the Ukraine Medical Top Grossing chart: the antidepressant tracker app Kurso isn't really taking off yet

What it is An iPhone app for people just starting antidepressants: medication reminders without guilt, dose adjustments tracked by treatment week, mood and side effects logged in a few taps, and a PDF generated for your doctor. No sign-up, data stays on the phone. Subscription is $2.99/month.

Why it's showing up It isn't really taking off: the bar on Ukraine's medical grossing chart is very low, and one or two subscriptions (possibly from the developer's personal network) are enough to land #36. Outside the Ukraine store, which has 1 ratings at 5 stars, every other store is 0.

DHow you could follow Don't build another standalone antidepressant tracker app. If you have doctors, counselors, or patient communities in your network, you could try it by doing what Apple Health doesn't: treatment-week tracking, side-effect templates, and a PDF for appointments. Everyone else can just take its privacy design and localized store titles.

Grade D: this niche already has eight or nine small apps, none of which has gained real traction. Users still have the free Medisafe, MyTherapy, and the built-in iPhone Health app. Kurso's chart placement comes from single subscriptions in small-country charts, so demand for paying hasn't been proven. What's missing is distribution, and followers have no ready-made channel to copy. Nobody knows about it yet

Est. monthly revenue (App Store) under $1KWe estimated this from its chart ranks and rating growth across storefronts, calibrated against verified revenue; typical error is 2–3x. Read it as a tier, not an exact number.

Data (updated daily) · Launched 2026-11-09 · Ukraine rating 1 · Charted in 11-20 of 1 stores
iOS · best category chart rank · by store
10020011-1211-1411-1611-1811-2085
Data 2026-11-12 → 2026-11-20 (9 days, 9 observations). Lower rank is higher; gaps mean it wasn't charted that day
iOS · ratings · Ukraine
00.5111-1211-1411-1611-1811-201
Data 2026-11-12 → 2026-11-20 (9 days, 9 observations). Apple doesn't publish download counts; rating growth is a proxy for downloads.

Kurso is an antidepressant medication helper built by one person on the side. It was listed on Nov 9, and a week later it appeared at #36 on the Ukraine App Store medical Top Grossing chart, ahead of the long-established Medisafe and MyTherapy. The ranking looks impressive, but the most likely explanation is one or two subscriptions. This developer's previous app already went through the same thing. This antidepressant tracker niche has produced eight or nine small apps this year, and none of them has gained real traction yet.

Morning 8:31, sertraline 100 mg

Kurso's homepage hero is a phone screenshot: "Sertraline 100 mg, Taken at 8:31", below that "Today's mood 4 / 5", and below that "Week 4 of your course — Steady and on track" (week 4 of the course, all steady). The headline reads: Take your meds. Notice how you feel. Gently.

It targets the first few months of antidepressant treatment. The drug hasn't kicked in yet, side effects show up first, doses keep getting adjusted step by step with a doctor, and this is when people are most anxious and most likely to skip doses or stop. Kurso's approach is concrete (App Store product page, 11-16):

  • Reminders without guilt: you can tap "Taken" or "Snooze" right in the notification. No streak counter, and missing a day doesn't trigger a red warning.
  • Organized by treatment week: follow your doctor's dosing plan step by step, with reminders and history updating as the dose goes up or down.
  • Log how you feel in a few taps: mood, anxiety, energy, sleep, plus common side effects like nausea, poor sleep, and "emotional blunting". Every two weeks you can take the PHQ-8 (depression) and GAD-7 (anxiety) scales that doctors commonly use.
  • A PDF for your doctor: doses, adherence, mood, scale scores, and dose changes in one place. Send it before an appointment or print it out.
  • Privacy taken to the extreme: no sign-up, no ads, no analytics, data stored only on the phone. Face ID locks the app, the journal can be locked separately, medication names can be hidden on the lock screen, and you can switch to a less obvious icon.

Free to download. Kurso Plus is $2.99/month or $29.99/year (in-app purchase list, not checked item by item). The store says it supports 15 languages, the website says 17. Store names aren't direct translations either: the Russian store uses "Kurso: Mental Health Med Log" and the German store uses "Antidepressiva-Tracker", using the search terms locals actually type.

Developer Andrii Hermanov has only two apps. The other is Lumi, a budgeting app released in January. Both sit under subdomains of herman-apps.com, whose main site is a template landing page. Lumi's website has Russian, Ukrainian, and Romanian versions. It looks like a programmer with a day job who builds apps on the side (inference).

How it reached #36

Kurso has only charted in the Ukraine store and has not entered any other store's charts:

DateUkraine chartRankScore
11-12Medical Top Free chart1670
11-13Medical Top Free chart1900
11-14Medical Top Free chart1400
11-15Medical Top Free chart860
11-16Medical Top Grossing361

Those 1 ratings average 5 stars and appeared the same day the chart placement did. The US, Russian, and German stores each show a rating of 0 (App Store, 11-16).

The Ukraine medical Top Grossing chart is very easy to get onto. On the Nov 16 chart, Mama Novum, a parenting app released the same day as Kurso, ranked #32, Medisafe #54, and MyTherapy #75. The top 50 also includes several small apps released this year by individual Ukrainian developers. An app listed for 7 days with only 1 ratings can rank above Medisafe, which suggests one or two subscriptions are enough to push into the top 40 (inference).

From the outside, there's no way to tell who bought those one or two: real users, the developer's acquaintances in Ukraine, or the developer testing in-app purchases. Looking at just that one day can't show that people are actually paying for subscriptions.

The same developer's previous app already went through this

Lumi has been out for 9 and a half months, and its total ratings add up to fewer than 20: 1 in the US store, 2 in the Russian store, and 12 in the Ukraine store (App Store, 11-16). On the grossing charts it almost always follows the same pattern: a single jump up, then a steady slide down every day:

  • Russian Finance Top Grossing chart: 11-01 #15 → 11-02 #26 → #40 → #50 → #62 → #76 → #82 → #89 → #110 → 11-10 #144;
  • Finland: 11-06 hit #20, then slid all the way down to 11-11 #63; Denmark: 10-31 hit #34, and 11-06 fell to 121;
  • Poland, Ireland, Singapore, the Philippines, Romania, Taiwan, and more than a dozen other stores all look the same.

Grossing charts rank by recent revenue. Charting for one day and then dropping a bit further each day, without ever climbing back, is what a single subscription looks like with no new revenue after it. Only Lumi's Ukraine store repeatedly jumped back into the top 50 (11-01 #41, 11-04 #35, 11-14 #35), the only store where it has any sustained revenue, and even there the volume is very small.

So Kurso charting in Ukraine and Lumi hitting #15 in the Russian store are the same signal: a multilingual app spread across dozens of small-country stores, where the category charts are easy to crack and a single subscription can push it up. It looks like it's taking off, but it isn't.

Where users come from: so far only native-language communities and store search

  • Store search + localized titles: titles in over a dozen languages, with local search terms in each store. This is confirmed work, but how many downloads it brings in can't be seen.
  • Personal network: both apps' ratings and rankings are concentrated in the Ukraine store, so the first users most likely came from the developer's own circle (inference).
  • Website and blog: Kurso's website is live, but its blog has only 2 posts ("How to talk to your doctor about drug effects", "Why you don't need an account"). Lumi has dozens of long-tail articles, plus a multilingual sitemap and calculator tool pages, which suggests this developer wants to go the search engine route. Kurso has only just started.
  • Ads, TikTok, X, Reddit, press: none found. On X, searching "Kurso" and "antidepressant tracker" over the past ~30 days returned 0 posts, and no Reddit threads or press coverage turned up.

This niche: eight or nine small apps, none with real traction

Between 2025 and 2026 years, a batch of apps appeared in the "antidepressant tracking / tapering" niche:

ProductLaunchedVolumeWhat it does
Symptom Tracker: With Claro (a small Portuguese company)2026-05US: 17 ratingsClosest to Kurso in positioning, with added tapering support; annual fee $29.99–49.99; has website articles and short Instagram videos, and bought one sponsored article
Taper: Medication Tapering App2025-03US: 28 ratingsTapering plans for antidepressants, benzodiazepines, and opioids, also promoting no sign-up and no uploads
DoseDown: Antidepressant Taper (Sweden, Nordic Social Media AB)2026-03US: 0 ratingsOnly covers SSRI/SNRI tapering, from a company that makes apps in bulk
QTc Tracker für SSRI & SNRI (German indie developer)2026-074 ratings on the German storePaid download, focused only on the ECG QTc metric; once reached #40 on the German medical paid chart
Medoro, MediMood, TaperMate, RxDown, and others2020–20260–5 ratingsMood-plus-medication combinations, or tapering calculators

The users really worth going after are held by these general-purpose products:

  • Medisafe: the top name in medication reminders. Since 2026 January has had a free tier that allows only 2 medications; premium is $59.88/year. People taking only one antidepressant can get by on the free tier, so there are fewer people pushed out by Medisafe's price increases than you might expect.
  • MyTherapy: free and full-featured, with an official page for self-tracking depression.
  • Bearable, Daylio, eMoods: mood and symptom tracking, with 6,720, 62,518, and 4,266 ratings in the US store respectively.
  • The built-in iPhone Health app: "Medications" can send reminders and "Mood" can log entries, free, with data stored locally. What it's missing is treatment-week tracking, side-effect templates, and a PDF for doctors. Some people on Reddit already recommend just using it.

In short, many people are testing niche splits, but no one has yet shown they can turn them into revenue. Kurso came later than withClaro and DoseDown, making it a follower.

Three things worth taking

  1. Privacy design for sensitive categories: no sign-up, data only on the device, medication names hidden on the lock screen, a separately locked journal, and an icon that doesn't reveal what the app is. These are easy to build and are real selling points for people taking antidepressants. Mental health, sexual health, and addiction apps can all copy them.
  2. Use local search terms in store titles instead of translating the English name directly: Russian "Mental Health Med Log", German "Antidepressiva-Tracker".
  3. Learn to read grossing charts: ranking #dozens in a small-country category chart doesn't mean real revenue. The telltale pattern of one subscription is "charted for a day, then dropped a bit more every day". What to look for is whether ratings are growing, and whether the app can stay on charts in several stores over time.

If it were you

One-line verdict (D): Don't build "yet another antidepressant tracker app". Eight or nine have already entered the space and none has real volume. Users have the free Medisafe and MyTherapy, plus the built-in Health app on their phones, and Kurso's own chart placement is just one or two subscriptions. The missing piece isn't features. It's how to bring these users in, and nobody has figured that out yet.

Who it suits: people who already have access to this audience: psychiatrists, therapists, pharmacists, or those running depression or tapering support communities who can get the product directly into users' hands. Or teams already building medication or mental health apps who could add "treatment-week tracking + side effects + doctor PDF" as a feature rather than as a separate app.

Who it doesn't suit: solo builders hoping to launch a subscription app and slowly build volume through store search. Kurso is in 15 languages with localized names in every store, and after a week of listing it got 1 ratings, all in Ukraine. It also doesn't suit people unwilling to deal with medical compliance: these apps need to state clearly "not a medical device, no medical advice, don't change your treatment plan yourself". If a user follows the app to taper and something goes wrong, the trouble is far bigger than in most other categories.

How to do it: find a channel first, then write code. If a doctor or community is willing to recommend the product, build the part Apple Health doesn't cover: treatment-week tracking, side-effect templates, and a PDF to take to appointments. Keep privacy to Kurso's standard. For pricing, try a one-time purchase: treatment has a start and an end, and subscribers are likely to cancel when they stop the medication (inference).

How to get users: Doctors and therapists recommend it when prescribing or at follow-up visits; people in patient communities share it. For search, write long-tail posts like "sertraline nausea week 3" or "escitalopram taper side effects" in the native language, not translated (inferred: search volume for these queries is unverified).

When is the window: No rush. No window is closing in this space. One question is still open: will people pay for it?

Signs you've got it wrong: ① Kurso stays on the Medical Top Grossing chart for two-plus weeks in any of the German, French or Japanese stores, rank 50, and its ratings climb into the dozens, which would mean multilingual listings plus search terms really bring in users; ② withClaro's US rating passes 200 before March 2027, or it starts running Meta ads consistently, which would mean someone has worked out acquisition cost; ③ a comparable product publicly reports over a thousand dollars a month in revenue.

---

Data and sources: App Store listings and ratings (Kurso, Lumi in the US, Ukraine, Russia and Germany stores, 11-16); App Store Ukraine Medical Top Free and Top Grossing charts (11-12 to 11-16); Lumi on the Finance Top Grossing charts in the Russia, Finland, Denmark and other stores (10-28 to 11-16); Germany Medical Top Paid (QTc Tracker); the official sites kurso.herman-apps.com, lumi.herman-apps.com and their blogs; competitor store pages and sites withclaro.com and usetaper.app; Medisafe free-tier limits from pillo.care, mojapteczka.pl and Reddit r/androidapps; public X posts from the last 30 days. Anything marked "inferred" or "unverified" is an estimate or assumption.

iOS store page ↗

Research notes: competitor table, acquisition evidence, full research report
Competitors
NameWhereLaunchedScaleHow it differs from this one
withClaro(Symptom Tracker: With Claro)iOS2026-05-2917 ratings in the US store; never charted; official SEO site, Instagram reels, and one sponsored articleClosest positioning, with added taper support, but priced higher; Kurso is cheaper, supports more languages and is more thorough on privacy
DoseDown: Antidepressant Taper(Nordic Social Media AB)iOS2026-03-040 ratings in the US store; also has an Android versionOnly handles SSRI/SNRI tapers, from a template-clone factory; Kurso covers the whole course of treatment
Taper: Medication Tapering AppiOS2025-03-2728 ratings in the US store; site usetaper.app; also has an Android versionTaper plans for multiple drugs (benzodiazepines, opioids, etc.); Kurso focuses on antidepressant courses and mood logging
Medoro / MediMood / TaperMate / RxDown / TaperTracer / QTc Tracker for SSRIiOS2020–2026All sit at 0–5 ratingsGeneric combos of mood and medication tracking, or taper calculators only; English only
MedisafeiOS2012Leader in medication reminders; the free tier allows only 2 drug from 2026-01, Premium $59.88/year; #54 on the Ukraine Medical Top Grossing chartGeneric medication reminders with no course-week tracking, side-effect templates or doctor reports; a free tier is enough for someone on a single drug
MyTherapyiOS2013Free; #75 on the Ukraine Medical Top Grossing chart; has a depression self-tracking content pageFree and comprehensive; Kurso is a niche version built specifically for antidepressants, with a gentler tone
Bearable / Daylio / eMoodsiOS2017–20206,720 / 62,518 / 4,266 ratings respectively in the US storeFocused on mood and symptom tracking; medication is a side feature
Apple Health "Medications" + "State of Mind"Big-company featuresiOS 16/17On every iPhoneFree and local, but no course-week tracking, side-effect templates or PDF for doctors
Where users come from
  • Confirmed multilingual store localization + organic traffic from small-country stores: supports 15 languages, the Russian title is "Mental Health Med Log" and the German title is "Antidepressiva-Tracker"; only the Ukraine store shows chart rank and ratings so far
  • Inferred the developer's personal network (Ukraine): Lumi has 12 ratings in Ukraine and only 1–2 in other stores; Kurso's only ratings and chart rank both come from Ukraine, on the same day
  • Confirmed official site + SEO blog: kurso.herman-apps.com is live, with only 2 blog posts; the same developer's Lumi has dozens of long-tail SEO articles, a multilingual sitemap and calculator tool pages
  • Inferred paid ads / TikTok / X / Reddit / media: 0 x-radar posts, none found by Brave or Jina search; no UTMs and no evidence of ads; TikTok could not be checked

Kurso: Antidepressant Tracker(ios_6821469023)

Verdict: it hasn't really taken off. Kurso is a antidepressant course assistant from Ukrainian indie developer Andrii Hermanov, launched on 2026-11-09 (medication reminders, mood and side-effect logging, a PDF report for doctors; subscription $2.99/month or $29.99/year). It was flagged because on 11-16 it hit #36 on the Ukraine Medical Top Grossing chart, but that chart has a very low bar, so the most likely explanation is a handful of subscriptions, probably from the developer's own circle in Ukraine. That doesn't show real conversion. The same developer's other app, Lumi, follows the same pattern: on a dozen small-country Finance Top Grossing charts it "charts for one day, then slips 10–30 spots every day", which is what isolated single purchases look like. What's worth watching is the category: "antidepressant course tracking" has spawned a batch of small apps over the past 2026 years, yet none has grown.

Regions checked: the appstore library was scanned across all stores (Kurso charted only in Ukraine; Lumi charted in 17 stores including Ukraine, Russia, Poland, Finland, Denmark, Ireland, Singapore, the Philippines, Romania, Uzbekistan, Lithuania and Taiwan); then iTunes lookup for the US, Ukraine, Russia and Germany.

---

1. What it is

  • App Store: apps.apple.com/app/id6821469023; first released 2026-11-09, version 1.0, Medical (secondary category Health & Fitness), free to download, requires iOS 17, about 24.6 MB (iTunes lookup, 2026-11-16).
  • Features (store description and official site kurso.herman-apps.com/):
    • Reminders that don't guilt you: mark "taken" or snooze right from the notification, no streak counting, and a missed dose never shows a red warning;
    • Organized by "week of the course": follow the doctor's dosing plan up or down step by step, with reminders and history adjusting along the way;
    • Log mood, anxiety, energy and sleep in a few taps, and track common side effects (nausea, insomnia, emotional numbness); optionally record blood pressure, pulse, blood glucose and temperature;
    • The recall card shows PHQ-8 / GAD-7 scales; one tap generates a PDF for your doctor;
    • Privacy: no account sign-up, no ads, no analytics; data stays on the phone; Face ID lock (the app and the diary can be locked separately); drug names can be hidden on the lock screen; and you can switch to a discreet icon.
  • Pricing: Kurso Plus $2.99/month or $29.99/year (recall card).
  • Languages: the store lists 15 (DA NL EN FI FR DE IT JA KO PL PT RU ES SV UK), and the official site says "17 languages". The Russia store name was changed to "Kurso: Mental Health Med Log" and the Germany store name to "Antidepressiva-Tracker", showing store optimization localized per market (iTunes lookup ru/de).
  • Developer: Andrii Hermanov (developer ID 1814089705), with only 2 apps under his name: Kurso, and Lumi: Budget & Expense Tracker, listed by 2026-01-30. Lumi's sellerUrl is a Telegram link to t.me/andrey_germanov; Kurso's official contact email is a personal Gmail; both apps sit under subdomains of herman-apps.com, and the main site is just a GoDaddy template page ("Tailored Software Solutions"). LinkedIn has ro.linkedin.com/in/andreygermanov, listed as "Senior Frontend Developer, React", which is probably the same person (unverified), possibly based in Romania; Lumi's official site has ru, uk and ro versions, which fits that guess. This looks like a solo developer with a day job who builds apps on the side.

2. Data: did it actually break out?

Kurso (appstore library app_day, only Ukraine records)

DatechartRankScore
2026-11-12Ukraine Medical Top Free1670
2026-11-13Ukraine Medical Top Free1900
2026-11-14Ukraine Medical Top Free1400
2026-11-15Ukraine Medical Top Free860
2026-11-16Ukraine Medical Top Grossing361(+1)
  • No chart presence in any other store; the rating counts in the US, Russia and Germany are all 0, and only Ukraine has 1 ratings (iTunes lookup, 11-16).
  • How low the bar is on the Ukraine Medical Top Grossing chart: on 11-16 this chart is full at #200; Kurso is at #36, right next to Mama Novum (also listed 11-09, at #32), Medisafe at #54 and MyTherapy at #75; the top 50 includes several small apps from Ukrainian solo developers launched in the past 2026 years (Malyatko, Baby Novum, BabyLeap, PillsCheck). An app listed 7 days ago with 1 ratings can rank ahead of Medisafe, which means one or two subscriptions are enough to make the top 40 (appstore library chart_rank, 2026-11-16).
  • The free chart is the same: #86 on the Ukraine Medical Top Free chart, which takes only a few downloads.

The same developer's Lumi (as a control, to see what scale this developer usually operates at)

Lumi has been listed for 9 months-and-a-half, with only 1 global rating (US), 2 (Russia) and 12 (Ukraine) (iTunes lookup, 11-16). Its chart history is almost all "jump up, then slide down every day":

  • Russia Finance Top Grossing: 11-01 #15 → 11-02 #26 → #40 → #50 → #62 → #76 → #82 → #89 → #110 → 11-10 #144;
  • Finland: 11-06 #20 → sliding all the way to 11-11 #63; Denmark: 10-31 #34 → 11-06 #121;
  • Only ua keeps bouncing back to the top 50 (11-01 #41, 11-04 #35, 11-14 #35). It's the only store with ongoing, if small, revenue.

Top Grossing ranks by recent revenue, so "charted for one day, then dropping every day with no return" is what a single subscription (or one renewal) coming in and then nothing new looks like. The recall reason "Lumi also charted on the Russia-store Top Grossing" is just a few one-off payments amplified on a small chart. It can't be used to prove this matrix play makes money (appstore library, app_day 10-28 to 11-16).

Bottom line: Kurso hit #36 on the Ukraine Top Grossing chart with 11-16, and the likeliest explanation is 1 Kurso Plus subscriptions at most, bought by people in the developer's own Ukrainian circle. Those 1 ratings showed up the same day. That doesn't count as proof that subscriptions are really converting.

3. Competitors

I searched the US App Store for "antidepressant tracker", "SSRI tracker", "taper tracker", "withdrawal taper" and "medication mood tracker" (iTunes Search, 11-16), and also looked up the names in the appstore library.

Direct competitors (antidepressant niche, a batch launched over the past 2025–2026 years, none with traction):

ProductPlatformLaunchedScaleDifferences from Kurso
withClaro (Symptom Tracker: With Claro, PINK ELEPHANT UNIPESSOAL LDA, Portugal)iOS + website2026-05-2917 ratings in the US store; never on any chart in the library; official site withclaro.com, Instagram reels promotion, and a sponsored article in Maryland Reporter 2026-06Nearly identical positioning (courses, dose changes, side effects, doctor reports), but adds "taper support"; the recall card lists an annual price of $29.99–49.99 and has an SEO content matrix; Kurso is cheaper and more thorough on privacy
DoseDown: Antidepressant Taper (Nordic Social Media AB, Sweden)iOS + Android2026-03-040 ratings in the US store; never chartedOnly handles SSRI/SNRI tapers, from a template-clone factory; Kurso covers the whole course of treatment
Medoro: Mood & Meds Tracker(Aivenya)iOS2026-05-190 ratingsGeneric mood + medication combo
MediMood: Medication & Mood(Karla Matosic)iOS2026-03-280 ratingsSame as above
Taper: Medication Tapering App(Taper Inc.)iOS + Android + usetaper.app2025-03-27US: 28 ratingsTaper plans (benzodiazepines, antidepressants, opioids), also pitched on "no sign-up, nothing on servers"
TaperMate / RxDown / Taper Community / TaperTracer / SafeTaperiOS2020–2026All sit at 1–5 ratingsTaper calculators or community
QTc Tracker for SSRI & SNRIiOS2026-07-14No dataOnly tracking the QTc heart-rate metric
Lemoon - Mood & Pill TrackeriOS2020-01-205 ratingsOlder mood + medication combo

Indirect rivals (general med reminders, mood/symptom trackers, and where Kurso really competes for users):

ProductPlatformLaunchedScaleDifference
MedisafeiOS / Android2012Leader in med reminders; free tier allows only 2 meds since 2026-01-01, Premium $59.88/year (pillo.care, mojapteczka.pl, Reddit r/androidapps)General med reminder; people on a single SSRI can use it within the free limit, so few people are actually pushed over by Medisafe's price hike
MyTherapy(smartpatient GmbH)iOS / Android2013Free; #75 in ua Medical Top Grossing; the website has a dedicated "depression self-tracking" pageFree, comprehensive, content marketing even covers depression
BearableiOS / Android2020US store 6,720 ratings; charted in 9 storesGeneral symptom and mood tracking
DaylioiOS / Android2017US: 62,518 ratingsMood diary, regardless of medication
eMoods (bipolar)iOS20174,266 ratingsBipolar mood chart, exportable for your doctor
Guava, CareClinic, EveryDose, Max Pill reminderiOS2018–2022Hundreds to tens of thousands of ratingsGeneral health or medication
Apple Health's "Medications" + "State of Mind"Big-company featuresiOS 16 / 17On every iPhoneFree, local, handles reminders and mood logging; gaps are no treatment-course weeks, no side-effect templates, and no PDF for doctors. Some Reddit users already recommend using it directly (r/TwoXADHD 2026-03)

Competitors: Yes, and quite a few. Over the past 2026 years, at least 6–8 small apps have appeared in the "antidepressant tracking / tapering" niche, none with real traction (0–28 ratings each), and none have charted in the stores. This shows many people are testing vertical splits, but no one has proven they make money yet.

4. Growth channels: where users come from

ChannelEvidenceConfirmed?
Organic traffic from small-country stores + localized store optimization15 languages, with store titles tailored to local search terms in each store (Russian store: "Mental Health Med Log", German store: "Antidepressiva-Tracker"); only the ua store has rankings and ratingsPartly confirmed (localization confirmed; how much traffic comes from search is unverified)
The developer's own network (Ukraine)Both apps have the most ratings in the ua store (Lumi 12, 1–2 in other stores); Kurso's only rating and only Top Grossing ranking both came from ua, on the same dayInferred, not confirmed
Website + SEO blogkurso.herman-apps.com is live, but the blog has only 2 posts ("how to talk to your doctor about drug effects", "why no account"), and there is no sitemap. Compare Lumi: dozens of long-tail posts (Apple Pay export, offline bookkeeping, MCP connecting to Claude/ChatGPT), a multilingual sitemap, and calculator tool pages. The developer's playbook is SEO, but Kurso has only just startedConfirmed in progress, results not yet visible
Paid acquisitionNo ads found (no sellerUrl, no UTM; the ad libraries don't track this app)No evidence
TikTok / X / Reddit / pressx-radar over the past 30 days: searches for "Kurso" and "antidepressant tracker" each return 0 results; Brave/Jina find no Reddit threads or media coverage; the TikHub endpoint returned no data this time, so TikTok is unverifiedNo evidence

5. Why it "broke out" (really, why it was re-surfaced)

  1. The bar for small-country category charts is very low: #36 in Ukraine's Medical Top Grossing probably takes just a couple of subscriptions. Listed for 7 days with 1 ratings, it ranked ahead of Medisafe (#54) and MyTherapy (#75) (appstore library, 11-16).
  2. The developer is based in Ukraine: both apps perform far better in the ua store on ratings and charts than elsewhere, so early paying users are likely acquaintances (inferred).
  3. The same developer's Lumi shows that "multilingual + small-country charts" repeatedly manufactures this kind of false signal: over 9 and a half months, across a dozen-plus stores, apps "charted on day one, slid daily", with combined ratings under 20.
  4. The product itself is carefully made: a sharp focus (the first few weeks of taking medication are the most anxious), gentle copy ("No streaks, no guilt"), and thorough privacy (no sign-up, local storage, hidden drug names on the lock screen, icon switching). These are plusses for people with depression, but they haven't turned into data yet.

6. Differentiation

  • Compared with general med reminders (Medisafe, MyTherapy, Apple Health): organized by treatment-course weeks, with doses adjustable step by step; antidepressant-specific side-effect templates and PHQ/GAD scales; can generate a PDF for doctors; tone deliberately "avoids creating guilt".
  • Compared with the same-niche withClaro, DoseDown, and Taper: the lowest price ($2.99/month); the most aggressive privacy (no sign-up, no analytics, hidden drug names on the lock screen, icon switching); covers "starting medication → adjusting dose → maintenance", not just tapering; the most languages (15–17, while competitors are essentially English-only).
  • These differentiators are not yet why it broke out, because it hasn't broken out. The re-surfacing is just noise from small-country charts. What may really matter is multilingual reach: non-English markets have almost no antidepressant-specific apps, and competition is minimal when German, French, Nordic, Japanese, or Korean users search in their native language. But so far there is a faint signal only in ua; every other store is still 0.

7. How many people can see it

Few people know about it: no public revenue, no TrustMRR listing, 0 posts on X, no media coverage, and no Reddit discussion. No one is copying it either: the same-niche withClaro (2026-05) and DoseDown (2026-03) came earlier, so it looks more like a follower than a leader.

8. What others can learn

  • Niche, non-English category Top Grossing charts can be used to test "will anyone pay", but you have to subtract purchases by acquaintances. The signature of a real one-time purchase is "charts on the day, then drops off a bit every day".
  • In sensitive health categories, a privacy setup of "no sign-up, data stays on device, hidden drug names on the lock screen, switch to an inconspicuous icon" is cheap to build and a strong selling point.
  • Store titles are tailored to local search terms in each store, rather than translating the English name directly (Russian store: Mental Health Med Log; German store: Antidepressiva-Tracker).
  • Be wary when reading signals: a small-country category Top Grossing rank of #dozens ≠ real revenue. Look at rating growth and whether the app stays on charts across multiple stores.

9. Still unclear

  • Whether the 11-16 Ukrainian subscriptions were bought by acquaintances, by the developer, or by real organic users, there's no way to tell.
  • The PHQ-8/GAD-7 references and the $2.99/$29.99 pricing on the re-surfacing card come from in-app purchase info in the stores, and were not verified item by item.
  • TikTok could not be checked (TikHub returned no data); the Meta/Google ad libraries don't track this app.
  • Listed for only 7 days, with 5 days of data in the library; whether search traffic picks up in the German, Nordic, and Japanese/Korean stores still needs 2–4 weeks of observation.
  • The developer's identity (Ukraine / Romania, full-time or part-time) is inferred only from LinkedIn, Telegram, and website language.

Sources

This article was written by AI from public data and the data we collect daily. Numbers are sourced, and inferences are labeled.